CD5: A New Partner for IL-6.
IL-6-STAT3 axis is known as a key factor of tumor progression. In this issue of Immunity, Yu and colleagues (2016) show that IL-6-binding CD5, rather than IL-6 receptor-α in B cells, amplifies STAT3 activation via JAK-STAT signaling to promote cancer.
Laboratory of Immune Regulation, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan.
Kazuya
K
Masuda
Laboratory of Immune Regulation, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan. Electronic address: kishimoto@ifrec.osaka-u.ac.jp.
Tadamitsu
T
Kishimoto
D001402:B-Lymphocytes / Q000276:immunology; D006801:Humans; D015850:Interleukin-6; D010766:Phosphorylation; D019947:Receptors, Interleukin-6; D050796:STAT3 Transcription Factor / Q000378:metabolism*; D015398:Signal Transduction / Q000276:immunology
D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D050796:STAT3 Transcription Factor